Cancer Stem Cell News Volume 5.01 | Jan 13 2016

    Cancer Stem Cell News 5.01 January 13, 2016

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  CSCN on Twitter

    Scientists Identify Protein Interaction that Defines an Aggressive Brain Tumor Subtype
    Scientists have identified a protein interaction that is a hallmark of an aggressive subtype of medulloblastoma and that may provide a new treatment strategy. The results also reveal why the proteins Myc and MycN, which were generally considered to be interchangeable, lead to two distinct subtypes of medulloblastoma when overexpressed in developing neurons. [Press release from St. Jude Children’s Research Hospital discussing publication in Cancer Cell] Press Release | Full Article | Graphical Abstract
    FREE Wallchart: Glioblastoma Multiforme

    PUBLICATIONS (Ranked by impact factor of the journal)
    Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer
    Scientists showed that polycomb repressive complex 2 (PRC2) is a critical regulator of KRAS-driven non-small cell lung cancer progression. Modulation of PRC2 by either Ezh2 overexpression or Eed deletion enhances KRAS-driven adenomagenesis and inflammation, respectively. [Cancer Cell]
    Abstract | Graphical Abstract | Press Release

    MiR-215 Is Induced Post-Transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B
    The authors report that hypoxia-induced miR-215 is vital for reprograming glioma-initiating cells to fit the hypoxic microenvironment via suppressing the expression of an epigenetic regulator KDM1B and modulating activities of multiple pathways. [Cancer Cell] Abstract | Graphical Abstract

    Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b–Mediated Malignant Progression
    Investigators examined the effects of coculturing human-derived adipocytes with established and primary breast cancer cells on tumorigenic potential. Prolonged culture of cancer cells with adipocytes or cytokines increased the proportion of mammosphere-forming cells and of cells expressing stem-like markers in vitro. [Cancer Res] Abstract | Full Article

    Preferential Expression of Functional IL-17R in Glioma Stem Cells: Potential Role in Self-Renewal
    Researchers explored the potential direct impact of IL-17−IL-17R interaction in gliomas. Immunohistochemistry and flow cytometry analysis of 12 tumor samples obtained from patients with high grade gliomas revealed that a considerable population of cells in all malignant gliomas expressed IL-17RA, with remarkable co-expression of the glioma stem cell markers CD133, Nestin, and Sox2. [Oncotarget] Full Article

    A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling
    Investigators determined whether A disintegrin and metalloproteinase domain 17 regulates the cancer stem cell phenotype in colorectal cancer and elucidated the downstream signaling mechanism that mediates cancer stem-ness. [Stem Cells Transl Med] Abstract | Full Article

    Low Adherent Cancer Cell Subpopulations Are Enriched in Tumorigenic and Metastatic Epithelial-to-Mesenchymal Transition-Induced Cancer Stem-Like Cells
    Investigators demonstrated that trypsin-sensitive breast and colon cancer cells subpopulations show increased ALDH activity, higher ability to exclude Hoechst 33342, enlarged proportion of cells with a cancer stem-like cell phenotype and are enriched in sphere- and colony-forming cells in vitro. [Sci Rep] Full Article

    miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells Through the Inhibition of DCLK1
    A PCR-based microRNA (miRNA) profiling analysis of normal colon stem cell (NCSCs) and colon cancer stem cell (CSCs) identified miRNAs which regulate colon CSC properties. miRNA-137 (miR-137) expression was downregulated in the colon CSCs compared to NCSCs, while doublecortin-like kinase 1 (DCLK1) mRNA was highly expressed in the colon CSCs but low in the NCSCs. [Mol Cancer Res] Abstract

    Mucin 1-Mediated Chemo-Resistance in Lung Cancer Cells
    Researchers demonstrated that non-small cell lung cancers survive paclitaxel (PTX) treatment. The proportion of the cancer stem cell marker, aldehyde dehydrogenase-positive cells, and epithelial–mesenchymal transition signaling protein levels were elevated in PTX-resistant A549 cells. [Oncogenesis] Full Article

    Dnajb8, a Member of the Heat Shock Protein 40 Family Has a Role in the Tumor Initiation and Resistance to Docetaxel but Is Dispensable for Stress Response
    Scientists established Dnajb8 knockout renal cell carcinoma (RCC) line cells and analyzed the cells to confirm the function of Dnajb8 in RCC cancer stem-like cells/cancer-initiating cells. [PLoS One] Full Article

    Learn More: Standardized Tools for Cancer Research

    Mantle Cell Lymphoma
    The authors review recent advances in the understanding of mantle cell lymphoma biology and outline their recommended approach to therapy, including choice of chemoimmunotherapy, the role of stem-cell transplantation, and mechanism-based targeted therapies, on the basis of a synthesis of the data from published clinical trials. [J Clin Oncol] Abstract

    Visit our reviews page to see a complete list of reviews in the Cancer Stem Cell research field.

    SELLAS Life Sciences Announces Preliminary Positive WT1 Cancer Vaccine Clinical Results in Multiple Myeloma Patients
    SELLAS Life Sciences Group reported positive results from the company’s Phase I/II clinical study of its WT1 cancer vaccine in patients with multiple myeloma following autologous stem cell transplantation. [Press release from SELLAS Life Sciences Group discussing research presented at the 34th Annual J.P. Morgan Healthcare Conference, San Francisco] Press Release

    From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.

    OncoMed Enrolls First Patient in Phase Ib Anti-RSPO3 Trial
    OncoMed Pharmaceuticals Inc. announced that the first patient has been enrolled and dosed in the Phase Ib portion of the Phase Ia/Ib clinical trial of anti-RSPO3. Anti-RSPO3 is the first drug in its class to target the R-spondin-LGR pathway, an important cancer stem cell pathway identified by OncoMed researchers. [OncoMed Pharmaceuticals Inc.] Press Release

    Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer
    Leaders from large pharma including Celgene and Amgen, biotech including NantWorks, NantKwest, Etubics, Altor Bioscience, and Precision Biologics, major academic cancer centers and community oncologists announced the launch of The National Immunotherapy Coalition, a historic alliance—in collaboration with Independence Blue Cross—with a singular focus: accelerating the potential of combination immunotherapies as the next generation standard of care in patients with cancer. [Business Wire] Press Release

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW Cell Culture 2016
    February 2-4, 2016
    London, United Kingdom

    Visit our events page to see a complete list of events in the Cancer Stem Cell community.

    NEW Professor – Cancer Immunotherapy (Stanford Cancer Institute)

    NEW Postdoctoral Scientist – Follicular Lymphoma (Herbert Irving Comprehensive Cancer Center)

    Postdoctoral Researcher – Prostate Cancer Biology (Roswell Park Cancer Institute)

    Postdoctoral Fellow – Cell and Molecular Biology of Leukemia (Virginia Commonwealth University)

    Postdoctoral Fellow – Cancer Stem Cell Biology (Cleveland Clinic)

    Postdoctoral Fellow – Cancer and Neurodegenerative Disease (University of Pennsylvania)

    Postdoctoral Position – Immunotherapy Targeting Cancer Stem Cells (Ecole Polytechnique Fédérale de Lausanne)

    Director – Cancer Center (The University of Hawai‘i Cancer Center)

    Assistant Member – Radioimmunotherapy (Fred Hutchinson Cancer Research Center)

    Faculty Positions – Cancer Pharmacology (Northwestern University)

    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us